The Latest Breaking News from Medtronic

The medtech market is thriving, thanks to the increasing investments and surging demand for enhanced efficiency. Therefore, investors could benefit from these trends by investing in fundamentally solid medical device stocks Becton, Dickinson and Company (BDX), Medtronic (MDT), and Abbott Laboratories (ABT), which are revolutionizing patient care. Keep reading.

Although Medtronic has lagged behind the broader S&P 500 index over the past three months, analysts remain moderately optimistic about the stock’s prospects.

The Dividend Aristocrats offer reliable yields; buying them when they are down provides a lever for total returns and a vehicle for market-beating returns.

Medtronic's stock price is in a classic head-and-shoulders reversal that could take it back to record highs within the next two years.

December S&P 500 E-Mini futures (ESZ24) are down -0.40%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.32% this morning as risk sentiment took a hit after Russian President Vladimir Putin updated the country’s nuclear doctrine, while investors awaited fresh data on the U.S. housing market and an earnings…

All eyes are on NVDA this week in a highly anticipated earnings report. We also have a few other big names all set to report such as Walmart, Snowflake, Target, Lowe’s, Palo Alto Networks, Deere & Company and Medtronic.

Medtronic has lagged behind the broader market over the past year, and analysts remain cautiously bullish on the stock’s prospects.

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Companies and organizations from Medtronic to the state of California are deploying AI to improve workflows and outcomes.

Medical tech business Medtronic eliminated $7.7 million in student debt, removing its degree requirements, while sending hundreds of employees back to school.

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.